Buscar resultados de ensayos clínicos

Patrocinado por

Carcinoma, Neuroendocrine - 23 Studies Found

Estado Estudiar
Not yet recruiting Nombre del estudio: Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Condición: High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Fecha: 2017-04-18
Intervenciones:
  • Drug: Pembrolizumab 200 mg eve
Not yet recruiting Nombre del estudio: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Condición:
Fecha: 2025-11-04
Completed Nombre del estudio: KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Condición: Carcinoma, Neuroendocrine
Fecha: 2014-08-21
Intervenciones: Drug: Selinexor Selective Inhibitor fo Nuclear Export (SINE)
Recruiting Nombre del estudio: An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis
Condición:
Fecha: 2025-11-04
Recruiting Nombre del estudio: A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
Condición:
Fecha: 2025-11-04
Completed Nombre del estudio: SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Condición:
  • Small Cell Lung Cancer
  • Large Cell Neuroendocrine Carcinoma

    • Fecha: 2015-07-06
    Intervenciones: Drug: SC-002 SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
Completed Nombre del estudio: Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
Condición: Neuroendocrine Carcinomas
Fecha: 2016-02-18
Intervenciones: Drug: cisplatinum and everolimus Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 o
Completed Nombre del estudio: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Condición: Neuroendocrine Carcinoma
Fecha: 2016-02-17
Intervenciones: Drug: Everolimus Maintenance therapy Other Name: Afi
Active, not recruiting Nombre del estudio: 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Condición: Neuroendocrine Carcinoma of the Lung and Thymus
Fecha: 2012-03-20
Intervenciones:
  • Drug: Pasireotide LAR 60 mg i.
Not yet recruiting Nombre del estudio: Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Condición: Neuroendocrine Carcinoma, Grade 3
Fecha: 2017-05-08
Intervenciones: Drug: Avelumab Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
<<< Previous | Next >>>